Zimmer Biomet lifts earnings guidance, shares trade near key technical levels

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 15:06.

Zimmer Biomet (US98956P1021) has recently raised its full-year earnings guidance while reaffirming a modest 1 to 3 percent revenue growth outlook for 2026, according to a recent fundamental analysis update. A Simply Wall St review of the guidance change highlights that the NYSE-listed shares have delivered a roughly 7.8 percent one-month return, even as the five-year total shareholder return remains markedly negative.

Guidance raise and recent performance

The latest guidance update from Zimmer Biomet points to full-year 2026 earnings per share in a range of 8.40 to 8.55 dollars, compared with prior expectations that were lower, while keeping the top-line growth range at 1 to 3 percent. The Simply Wall St article notes that the shares have gained about 3.4 percent over the past seven days, yet the five-year total return is still down close to 40 percent, underperforming broader healthcare peers such as Intuitive Surgical.

Zimmer Biomet last reported quarterly results on 2026-04-28, posting earnings per share of 2.09 dollars, which exceeded the consensus estimate of 1.86 dollars by 0.23 dollars, as summarized in a recent institutional-holdings review. MarketBeat’s coverage of a first-quarter SEC filing points out that analysts on average now anticipate full-year earnings of around 8.49 dollars per share, broadly aligned with the revised guidance range.

Analysts, institutions and technical picture

On the analyst side, Leerink Partners initiated coverage of Zimmer Biomet in April with a Hold rating and a 101 dollar price objective, while other research aggregators have flagged upgrades from Hold to Buy in May, according to the same MarketBeat summary. That report also shows that institutional investors and hedge funds collectively hold close to 89 percent of the stock, underlining the strong role of professional capital in the NYSE-traded name.

From a technical perspective, Zimmer Biomet shares recently closed around 91.01 dollars on 2026-06-25, leaving the stock between a cited resistance level near 95.29 dollars and support around 84.10 dollars. Data from TradingKey’s technical overview assigns the shares a price momentum score of about 9.2 and indicates four buy signals versus one sell signal across key indicators, with the 50-day and 200-day moving averages both pointing to a still constructive medium-term trend.

The product behind the stock

Zimmer Biomet generates the bulk of its revenue from orthopedic reconstructive implants, with its knee and hip systems forming the core of the portfolio and a 2025 revenue figure reported at about 8.23 billion dollars. A company profile by BCC Research describes the group’s offering as spanning knee replacements, sports medicine implants, extremities, trauma products and craniomaxillofacial and thoracic devices, complemented by digital and robotic surgical platforms that increasingly rely on data and analytics.

Where the shares trade today

Zimmer Biomet shares (US98956P1021) last closed on the NYSE at 91.01 dollars on 2026-06-25 at 16:00 Eastern Time, according to TradingKey price data.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical performance is not a reliable indicator of future results, and readers should conduct their own research or consult a qualified financial advisor before making investment decisions.